Henry Schein Inc. closed 10.96% short of its 52-week high of $82.49, which the company reached on February 5th.

Henry Schein Inc. closed 9.71% below its 52-week high of $82.49, which the company reached on February 5th.

Melville, New York-based Henry Schein, Inc. (HSIC) provides healthcare products and services to office-based dental and medical practitioners, and alternate sites of care worldwide. With a market cap ...

Henry Schein, Inc. (NASDAQ:HSIC) is one of the 13 Cheap Mid-Cap Stocks to Add to Your Portfolio. On June 16, Leerink Partners ...

According to Benzinga Pro, Henry Schein's peer group average for short interest as a percentage of float is 4.30%, which means the company has more short interest than most of its peers. Did you know ...

PITTSBURGH — Pittsburgh Pirates catcher Henry Davis found himself in a great situation to help his team in their latest game vs. the San Diego Padres at Petco P ...

Henry Schein reaffirmed its adjusted annual profit forecast of $4.80 to $4.94 per share, compared with analysts' average estimate of $4.86 per share, according to data compiled by LSEG.

Nine analysts surveyed by Zacks expected $3.23 billion. Henry Schein expects full-year earnings in the range of $4.80 to $4.94 per share. _____ ...

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories.

Looking ahead, Henry Schein projects total sales growth of 2-4% for 2025, with non-GAAP diluted EPS expected to range between $4.80 and $4.94.

Henry Schein's market leadership and strategic acquisitions across various healthcare segments make it a solid investment, warranting a soft 'buy' rating for the stock. Read the full report.

Earnings vs. Forecast Henry Schein's Q4 2024 results showed an EPS of $1.19, missing the forecast by 3.25%. Revenue was $3.19 billion, falling short by 4.78%.